Dice Molecules Holdings is a biotechnology business based in the US. Dice Molecules Holdings shares (DICE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $47.55 – the same closing value as a week prior. Dice Molecules Holdings employs 71 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $47.55 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $45.41 |
| 200-day moving average | $34.82 |
| Wall St. target price | $48.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.17 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $47.55 from 2023-08-18
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-13) | N/A |
| 1 year (2023-10-13) | N/A |
|---|---|
| 2 years (2022-10-17) | 32.53% |
| 3 years (2021-10-15) | 78.09% |
| 5 years (2019-10-13) | N/A |
| Gross profit TTM | $-56,075,000 |
|---|---|
| Return on assets TTM | -14.02% |
| Return on equity TTM | -21.6% |
| Profit margin | 0% |
| Book value | $11.89 |
| Market Capitalization | $2.3 billion |
TTM: trailing 12 months
DICE Therapeutics, Inc. , a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.